FY2029 Earnings Forecast for KYTX Issued By Leerink Partnrs

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Investment analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for shares of Kyverna Therapeutics in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings of ($4.19) per share for the year. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.29) per share.

Several other equities research analysts also recently issued reports on KYTX. HC Wainwright dropped their price objective on Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Wednesday, November 20th. Wells Fargo & Company reduced their price target on shares of Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, November 15th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Kyverna Therapeutics currently has a consensus rating of “Buy” and an average target price of $25.71.

Kyverna Therapeutics Stock Performance

Shares of KYTX opened at $3.00 on Friday. Kyverna Therapeutics has a 12 month low of $3.00 and a 12 month high of $35.06. The stock’s 50-day moving average is $3.91 and its two-hundred day moving average is $5.45.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings results on Wednesday, November 13th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.01. The business had revenue of $0.01 million during the quarter.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its holdings in Kyverna Therapeutics by 15.8% during the third quarter. JPMorgan Chase & Co. now owns 2,387,352 shares of the company’s stock worth $11,674,000 after buying an additional 326,095 shares during the last quarter. Novo Holdings A S boosted its stake in shares of Kyverna Therapeutics by 5.7% during the third quarter. Novo Holdings A S now owns 1,850,000 shares of the company’s stock valued at $9,046,000 after purchasing an additional 100,000 shares in the last quarter. Franklin Resources Inc. raised its position in Kyverna Therapeutics by 13.8% during the 3rd quarter. Franklin Resources Inc. now owns 936,961 shares of the company’s stock worth $4,582,000 after purchasing an additional 113,922 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Kyverna Therapeutics by 32.8% in the 2nd quarter. Millennium Management LLC now owns 923,082 shares of the company’s stock valued at $6,923,000 after purchasing an additional 227,988 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Kyverna Therapeutics by 19.0% during the third quarter. Geode Capital Management LLC now owns 443,312 shares of the company’s stock worth $2,168,000 after purchasing an additional 70,714 shares during the period. Institutional investors and hedge funds own 18.08% of the company’s stock.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.